Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.42 |
| ▸ | TDO2 | P48775 | 16/20 | 0.42 |
| ▸ | IDO2 | Q6ZQW0 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26614200 | 0.92 | IDO1 (0.41) | IDO1TDO2IDO2MMP13 | |
| SCHEMBL26614194 | 0.92 | IDO1 (0.41) | IDO1TDO2IDO2MMP13 | |
| SCHEMBL26861420 | 0.91 | IDO1 (0.49) | IDO1TDO2IDO2CA12CA1 | |
| SCHEMBL30639069 | 0.84 | IDO1 (0.46) | IDO1TDO2IDO2CA12CA1 | |
| SCHEMBL30639096 | 0.81 | IDO1 (0.63) | IDO1TDO2IDO2 | |
| SCHEMBL26614110 | 0.80 | IDO1 (0.46) | IDO1TDO2IDO2 | |
| SCHEMBL30639055 | 0.78 | IDO1 (0.46) | IDO1TDO2IDO2 | |
| SCHEMBL26861414 | 0.77 | TDO2 (0.49) | IDO1TDO2IDO2 | |
| SCHEMBL26614237 | 0.76 | IDO1 (0.46) | IDO1TDO2IDO2 | |
| SCHEMBL26614234 | 0.76 | IDO1 (0.46) | IDO1TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4514804-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | Viscient Bio, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | IDO2, IDO1, TPSB2 | IDO1 2/4885TDO2 8/4885IDO2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.